yervoy iframe

Article

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Related Content
An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 15th 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 15th 2025
Podcast
It was noted that in those with a CTFI of more than 3 months but less than or equal to 6 months, a “promising” number of durable responses was observed.

Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC

Tim Cortese
August 15th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 15th 2025
Podcast
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 15th 2025
Article
Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.

HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC

Roman Fabbricatore
August 15th 2025
Article